FL is a disease that for most runs a course of moving from periods of remission into relapse and back again and most patients experience multiple relapses over the course of their disease which can run for years or decades. For a small number of patients, the disease progresses earlier, and they can face 5-year survival rates as low as 50%. Like many cancers FL is genetically not just one disease, so to find cures will require a range of therapies to help a range of people.
This rests on finding the right drug to be provided to the right patient at the right time.
The CURE FL Awards are a call for transformative projects in areas of treatment that we have identified as being the most likely to deliver rapid progress towards a cure.
The CURE FL Awards (cycle 1) will focus on work in two areas as the most likely to lead to curative therapies available to FL patients as soon as possible: cellular immunotherapy, CAR-T (chimeric antigen receptor T cells) and others, and also targeted therapies, either as standalone treatments or in combination with other treatments.